Parabilis Medicines, Inc.

Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis

Parabilis Medicines initiated a dose-ranging clinical cohort of zolucatetide in familial adenomatous polyposis as part of its ongoing Phase 1/2 trial. Early proof-of-concept data showed significant reductions in duodenal polyp burden in two FAP patients — from Spigelman Stage IV to near-normal and Stage II to Stage I — with a favorable safety profile to date. Additional data from FAP patients with desmoid tumors is expected in Q1 2027, and a Phase 3 registrational trial in desmoid tumors is planned; there are currently no approved systemic therapies for FAP.

•11d ago

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors

Parabilis Medicines appointed Dr. Craig L. Tendler to its Board of Directors, adding a leader with over 30 years of experience in oncology drug development. Dr. Tendler previously held leadership roles at Johnson & Johnson, where he helped secure more than 30 regulatory approvals and 13 FDA Breakthrough Therapy designations. The company expects his expertise in clinical development and medical affairs to support the advancement of zolucatetide and the Helicon therapeutic pipeline.

•2mo ago

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

Parabilis ended the second quarter with $1.1 billion in cash following its $770.5 million IPO, providing a financial runway expected to fund operations into 2030. The company remains on track to initiate a Phase 3 registrational trial for its lead asset zolucatetide in desmoid tumors in the first half of 2027, with plans to engage the FDA in the fourth quarter of this year. Parabilis also detailed its strategic collaboration with Regeneron, noting the receipt of $125 million in upfront cash and equity investment with the potential for over $2.2 billion in future milestone payments.

•2mo ago

Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Parabilis Medicines closed its upsized initial public offering, selling 38.5 million shares at $20.00 per share for gross proceeds of $770.5 million. The offering included the full exercise of the underwriters' option and a concurrent private placement of 4.17 million shares to Regeneron Pharmaceuticals at $18.00 per share, raising an additional $75 million. Including the private placement and the conversion of a $50 million SAFE, the company has raised significant capital in 2026 to support its clinical-stage pipeline and Helicons platform.

•4mo ago